China Universal Asset Management Co. Ltd. Invests $326,000 in 10x Genomics, Inc. (NASDAQ:TXG)

China Universal Asset Management Co. Ltd. acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 22,687 shares of the company’s stock, valued at approximately $326,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TXG. GAMMA Investing LLC boosted its stake in shares of 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the third quarter worth $35,000. Blue Trust Inc. increased its holdings in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of 10x Genomics in the 3rd quarter valued at $46,000. Finally, Venturi Wealth Management LLC boosted its holdings in shares of 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after acquiring an additional 2,240 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Citigroup lowered their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a research report on Thursday, October 10th. Canaccord Genuity Group decreased their price target on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, October 10th. UBS Group cut their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group decreased their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, 10x Genomics has an average rating of “Moderate Buy” and a consensus price target of $23.86.

10x Genomics Stock Performance

10x Genomics stock opened at $15.00 on Monday. 10x Genomics, Inc. has a 52-week low of $12.95 and a 52-week high of $51.22. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.80 and a beta of 1.83. The stock’s 50 day moving average price is $15.16 and its two-hundred day moving average price is $17.74.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.